[go: up one dir, main page]

AR059182A1 - Utilizacion de 2-imidazoles para el tratamiento de trastornos del snc,proceso para obtener los compuestos - Google Patents

Utilizacion de 2-imidazoles para el tratamiento de trastornos del snc,proceso para obtener los compuestos

Info

Publication number
AR059182A1
AR059182A1 ARP070100321A ARP070100321A AR059182A1 AR 059182 A1 AR059182 A1 AR 059182A1 AR P070100321 A ARP070100321 A AR P070100321A AR P070100321 A ARP070100321 A AR P070100321A AR 059182 A1 AR059182 A1 AR 059182A1
Authority
AR
Argentina
Prior art keywords
disorders
formula
compound
compounds
naphthalen
Prior art date
Application number
ARP070100321A
Other languages
English (en)
Inventor
Marius Hoener
Sabine Kolczewski
Henri Stalder
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38229078&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR059182(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of AR059182A1 publication Critical patent/AR059182A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4168—1,3-Diazoles having a nitrogen attached in position 2, e.g. clonidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Child & Adolescent Psychology (AREA)
  • Addiction (AREA)
  • Anesthesiology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente está relacionada con la utilizacion de los compuestos de formula (1) en la que: R es H, hidroxi, alquilo inferior, alcoxi inferior, halogeno, alquilo inferior sustituido con un halogeno, o es 4-(CH2)2:C(O)-naftilo; X es -S- o -NH-; arilo es un grupo aromático, seleccionado de entre fenilo, naftalen-1-ilo, naftalen-2-ilo o 5,6, 7,8-tetrahidronaftalen-1-ilo, hetarilo es un grupo aromático, que contiene al menos un átomo de N o S en el anillo, seleccionado de entre el grupo que consiste en tiofen-3-ilo o pirimidin-5-ilo; n es 1, 2 o 3; y con sus sales, mezclas racémicas, enantiomeros, isomeros opticos y formas tautoméricas farmacéuticamente activas para la obtencion de medicamentos parca el tratamiento de la depresion, trastornos de ansiedad, trastorno bipolar, trastorno de hiperactividad con déficit de atencion (THDA), trastornos relacionados con el estrés, trastornos psicoticos como la esquizofrenia, enfermedades neurologicas como la enfermedad de Parkinson, trastornos neurodegenerativos como la enfermedad de Alzheimer, epilepsia, migrana, hipertension, abuso de sustancias y trastornos metabolicos como los trastornos alimentarios, diabetes, complicaciones diabéticas, obesidad, dislipidemia, trastornos en el consumo y asimilacion de la energía, trastornos y defectos en la homeostasis de la temperatura corporal, trastornos del sueno y el ritmo circadiano, y trastornos cardiovasculares. Reivindicacion 8: Los métodos para la obtencion de compuestos de formula (1) de acuerdo con las reivindicaciones 1-7, cuyos procesos comprenden c) c) hacer reaccionar un compuesto de formula (2) con una etilendiamina de formula H2NCH2CH2NH2 para dar un compuesto de formula (3) en el que R y n son como se ha definido en la reivindicacion 1, o d) hacer reaccionar un compuesto de formula (4) con un compuesto de formula (5) para dar un compuesto de formula (6) en el que los sustituyentes son como se han definido en la reivindicacion 1, y si se desea, convertir los compuestos obtenidos en sales de adicion ácida farmacéuticamente aceptables.
ARP070100321A 2006-01-27 2007-01-25 Utilizacion de 2-imidazoles para el tratamiento de trastornos del snc,proceso para obtener los compuestos AR059182A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP06100953 2006-01-27

Publications (1)

Publication Number Publication Date
AR059182A1 true AR059182A1 (es) 2008-03-12

Family

ID=38229078

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP070100321A AR059182A1 (es) 2006-01-27 2007-01-25 Utilizacion de 2-imidazoles para el tratamiento de trastornos del snc,proceso para obtener los compuestos

Country Status (12)

Country Link
US (1) US20070197569A1 (es)
EP (1) EP1981498A2 (es)
JP (1) JP2009524619A (es)
KR (1) KR20080090546A (es)
CN (1) CN101370500A (es)
AR (1) AR059182A1 (es)
AU (1) AU2007213887A1 (es)
BR (1) BRPI0707308A2 (es)
CA (1) CA2637292A1 (es)
IL (1) IL192877A0 (es)
TW (1) TW200800172A (es)
WO (1) WO2007090720A2 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2913886B1 (fr) 2007-03-22 2012-03-02 Guerbet Sa Utilisation de nanoparticules metalliques dans le diagnostique de la maladie d'alzheimer
EP2173719A1 (en) 2007-07-03 2010-04-14 F. Hoffmann-Roche AG 4-imidazolines and their use as antidepressants
GB2466622A (en) * 2008-12-23 2010-06-30 Trinity College Dublin Alpha2-Adrenoceptor Ligands
EP2765131B1 (en) 2013-02-08 2016-11-23 Arevipharma GmbH Process for the production of Moxonidine
WO2017210616A1 (en) * 2016-06-02 2017-12-07 Purdue Pharma L.P. Trace amine associated receptor 1 agonists and partial agonists for pain treatment
US20240002369A1 (en) * 2020-11-12 2024-01-04 3Z Ehf Novel treatments of attention deficit/hyperactivity disorder

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3236857A (en) * 1961-10-09 1966-02-22 Boehringer Sohn Ingelheim 2-(phenyl-amino)-1, 3-diazacyclopentene-(2) substitution products
US3190802A (en) * 1961-10-09 1965-06-22 Boehringer Sohn Ingelheim Shaving composition and method of using same
BE754820R (fr) * 1969-08-13 1971-02-15 Schering Ag Nouveaux derives de pyrimidine, leurs procedes de preparation et leurs
US3818094A (en) * 1969-08-28 1974-06-18 Boehringer Sohn Ingelheim Hypotensive pharmaceutical compositions containing certain 2-anilino-1,3-diazacyclopentenes-(2)
US3622579A (en) * 1969-08-28 1971-11-23 Boehringer Sohn Ingelheim Derivatives of 2-anilino-1,3-diazacyclopentene-(2)
DE2446758C3 (de) * 1974-10-01 1979-01-04 C.H. Boehringer Sohn, 6507 Ingelheim 2-(2-Fluor-6-trifluormethylphenylimino)-imidazolidin, dessen Säureadditionssalze, Verfahren zur Herstellung dieser Verbindungen und deren Verwendung bei der Bekämpfung der Hypertonie
US4125620A (en) * 1974-10-01 1978-11-14 Boehringer Ingelheim Gmbh 2-[(2',6'-Disubstituted-phenyl)-imino]-imidazolidines and salts thereof
DE2849537C2 (de) * 1978-11-15 1983-03-17 Beiersdorf Ag, 2000 Hamburg Substituierte 5-(2-Imidazolin-2-yl)-aminopyrimidine, Verfahren zu deren Herstellung und diese enthaltende Arzneimittel
US4323570A (en) * 1978-11-15 1982-04-06 Beiersdorf Aktiengesellschaft Substituted aminopyrimidines
CA2211325C (en) * 1993-10-13 2006-08-15 H. Joseph Horacek Extended release clonidine formulation
US6391871B1 (en) * 1996-09-20 2002-05-21 John W. Olney Preventing neuronal degeneration in Alzheimer's disease
NO980546L (no) * 1997-02-11 1998-08-12 Lilly Co Eli Farmas°ytiske midler
US5866579A (en) * 1997-04-11 1999-02-02 Synaptic Pharmaceutical Corporation Imidazole and imidazoline derivatives and uses thereof
SE9901295D0 (sv) * 1999-04-13 1999-04-13 Jan Hedner Sätt och medel för att förebygga, behandla och diagnostisera kardiovaskulära komplikationer hos patienter med obstruktiv sömnapné
EP1319070A2 (en) * 2000-09-12 2003-06-18 Oregon Health & Science University Mammalian receptor genes and uses
CA2427900A1 (en) * 2000-11-14 2002-05-23 F. Hoffmann-La Roche Ag Substituted 2-phenylaminoimidazoline phenyl ketone derivatives as ip antagonists
IL147921A0 (en) * 2002-01-31 2002-08-14 Abdulrazik Mohammad A method for treating central nervous system disorders by ocular dosing
US20050222270A1 (en) * 2004-02-26 2005-10-06 Olney John W Prolonged administration of NMDA antagonist drug and safener drug to create improved stable neural homeostasis

Also Published As

Publication number Publication date
EP1981498A2 (en) 2008-10-22
BRPI0707308A2 (pt) 2011-05-03
KR20080090546A (ko) 2008-10-08
IL192877A0 (en) 2009-02-11
WO2007090720A2 (en) 2007-08-16
CN101370500A (zh) 2009-02-18
US20070197569A1 (en) 2007-08-23
CA2637292A1 (en) 2007-08-16
TW200800172A (en) 2008-01-01
JP2009524619A (ja) 2009-07-02
AU2007213887A1 (en) 2007-08-16
WO2007090720A3 (en) 2007-09-20

Similar Documents

Publication Publication Date Title
AR059206A1 (es) Uso de derivados de 4-imidazol para trastornos del snc
AR059182A1 (es) Utilizacion de 2-imidazoles para el tratamiento de trastornos del snc,proceso para obtener los compuestos
BR112013024312A2 (pt) derivados de amina heterocíclica
AR059207A1 (es) Uso de derivados de 2-imidazol para el tratamiento de trastornos del snc
CO6321133A2 (es) Nuevas 2-aminooxazolinas como ligandos taar1 para trastornos cns
ECSP11010782A (es) Derivados de 4,5-dihidro-oxazol-2-ilo
MY176030A (en) Substituted benzamide derivatives
ECSP12012098A (es) Derivados de arilmetoxi isoindolina y composiciones que los comprenden y métodos para utilizar los mismos
AR067772A1 (es) Derivados piperazinicos de nicotinamida, medicamentos que los contienen, proceso para prepararlos y usos de los mismos para el tratamiento de trastornos asociados al sistema nervioso, cardiovascular y/o trastornos metabolicos.
AR063327A1 (es) Aminometil-4-imidazoles. procesos de obtencion y composiciones farmaceuticas
ECSP13013072A (es) Derivados de pirazol
MA35194B1 (fr) Derives de benzamide substitues
MX2017001096A (es) Derivados de 2-oxa-5-azabiciclo[2.2.1]heptan-3-ilo.
AR075530A1 (es) Nuevas orto-aminoamidas para el tratamiento del cancer
AR089691A1 (es) Derivados heterociclicos
MX377195B (es) Derivados de morfolina-piridina.
MX2009005920A (es) Nuevos 2-imidazoles como ligandos para receptores asociados con trazas de amina.
BR112015009990A2 (pt) derivados de pirazina
MX2016012624A (es) Derivados de 5-oxa-2-azabiciclo[2.2.2]octan-4-ilo y 5-oxa-2-azabiciclo[2.2.1]heptan-4-ilo como modularores de los receptores asociados a la amina de trazas 1 (taar1).
AR063811A1 (es) 4-imidazoles sustituidos
AR101339A1 (es) Derivados del 6-amino-5,6,7,8-tetrahidronaftalen-2-ilo o del 3-aminocroman-7-ilo
AR067675A1 (es) 2-azetidinametanoaminas y 2-pirrolidinametanoaminas como ligandos de taar, un metodo para su preparacion y su uso en la fabricacion de un medicamento para el tratamiento de trastornos del snc.
AR076979A1 (es) 2- aminooxazolinas como ligandos de taar1
AR070007A1 (es) Derivados naftalenicos, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen
RU2017106928A (ru) Замещенные производные пиразино[2,1-а]изохинолина для лечения заболеваний цнс

Legal Events

Date Code Title Description
FA Abandonment or withdrawal